Want to see NGEN full AI Analyst Report?
NGEN Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NGEN Stock 12 Month Forecast
Average Price Target
$10.33
▲(153.89% Upside)
| Highest Price Target$15.00 | Average Price Target$10.33 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$18→$15
Buy
268.55%
Upside
Reiterated
07/14/26
Leerink Partners
$10
Buy
145.70%
Upside
Initiated
07/13/26
TD Cowen
―
Buy
―
Initiated
06/11/26
Stifel Nicolaus
$6
Buy
47.42%
Upside
Reiterated
05/21/26
Lucid Capital
$18
Buy
342.26%
Upside
Initiated
04/15/26
Research Capital
$5.5
Buy
35.14%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group
$10→$12
Buy
194.84%
Upside
Assigned
04/09/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$18→$15
Buy
268.55%
Upside
Reiterated
07/14/26
Leerink Partners
$10
Buy
145.70%
Upside
Initiated
07/13/26
TD Cowen
―
Buy
―
Initiated
06/11/26
Stifel Nicolaus
$6
Buy
47.42%
Upside
Reiterated
05/21/26
Lucid Capital
$18
Buy
342.26%
Upside
Initiated
04/15/26
Research Capital
$5.5
Buy
35.14%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group
$10→$12
Buy
194.84%
Upside
Assigned
04/09/26
Best Analysts Covering NervGen Pharma
3 Months
Success Rate
2/3 ratings generated profit
Average Return
-3.90%
Copying Andre Uddin's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -3.90% per trade.
1 Year
Success Rate
6/11 ratings generated profit
Average Return
+9.35%
Copying Justin Keywood's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +9.35% per trade.
2 Years
Success Rate
2/11 ratings generated profit
Average Return
-6.37%
Copying Justin Keywood's trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -6.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NGEN Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
6
7
8
5
Buy
1
5
5
5
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
11
12
13
6
Each month's total comprises the sum of three months' worth of ratings.
NGEN Financial Forecast
NGEN Stock Forecast FAQ
What is NGEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Nervgen Pharma Corp’s 12-month average price target is 10.33.
What is NGEN’s upside potential, based on the analysts’ average price target?
Nervgen Pharma Corp has 153.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NGEN a Buy, Sell or Hold?
Nervgen Pharma Corp has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Nervgen Pharma Corp’s price target?
The average price target for Nervgen Pharma Corp is 10.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $6.00. The average price target represents 153.89% Increase from the current price of $4.07.
The highest analyst price target is $15.00 ,the lowest forecast is $6.00. The average price target represents 153.89% Increase from the current price of $4.07.
What do analysts say about Nervgen Pharma Corp?
Nervgen Pharma Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of NGEN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.